Has Vijay Bahl, MD received payments from drug or device companies?

Yes. Drug and device makers reported $997,685 in general payments to Vijay Bahl, MD across 2,910 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vijay Bahl, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vijay Bahl, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vijay Bahl, MD

Endocrinology, Diabetes & Metabolism · Pittsburgh, PANPI 1912084625

Payments from drug & device makers

$997,685in general payments, 2019–2025

Across 2,910 payments — averaging $342.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$408K
Novo Nordisk$153K
Bayer$100K
Johnson & Johnson$86K
Sanofi-aventis U.S. LLC$69K
AstraZeneca$62K
plus $120K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	747	$408,367
Novo Nordisk	493	$152,660
Bayer	152	$99,923
Johnson & Johnson	120	$86,090
Sanofi-aventis U.S. LLC	226	$69,374
AstraZeneca(2 entities)	177	$61,749
Boehringer Ingelheim	151	$29,642
Ascendis Pharma Endocrinology Inc	25	$24,955
Amarin Pharma, Inc.	41	$16,815
Amgen(2 entities)	86	$16,011
Merck	68	$8,921
AbbVie	105	$7,043
Esperion Therapeutics, Inc.	18	$4,400
Zealand Pharma US, Inc.	11	$1,926
Amneal Pharmaceuticals LLC	111	$1,882
Dexcom, Inc.	101	$1,701
BD	32	$883
Cequr Corporation	4	$867
Abbott	56	$754
Corcept Therapeutics	22	$449
Medtronic(2 entities)	19	$436
Astellas Pharma US Inc	11	$307
Novartis	13	$212
Embecta Corp.	7	$203
Insulet Corporation	11	$196
Xeris Pharmaceuticals, Inc.	10	$165
Tandem Diabetes Care, Inc.	8	$149
Mannkind Corporation	7	$148
Madrigal Pharmaceuticals	9	$145
Pfizer	7	$138
Sequel Med Tech, LLC	5	$122
Antares Pharma, Inc.	6	$110
Kowa Pharmaceuticals America, Inc.	5	$88
E.r. Squibb & Sons, L.L.C.	4	$67
IBSA Pharma Inc.	3	$60
Neurocrine Biosciences, Inc.	2	$59
Amphastar Pharmaceuticals, Inc.	3	$52
Currax Pharmaceuticals LLC	3	$42
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$40
Arbor Pharmaceuticals, Inc.	2	$39
Radius Health, Inc.	2	$39
Nevro Corp.	2	$38
GSK	2	$37
Takeda Pharmaceuticals U.S.A., Inc.	2	$36
BETA Bionics, Inc.	2	$31
Averitas Pharma Inc.	1	$30
Acerus Pharmaceuticals Corporation	2	$30
Vivus LLC	2	$26
Valeritas, Inc.	1	$23
Endo Pharmaceuticals Inc.	1	$22
Rhythm Pharmaceuticals, Inc.	1	$21
Ultragenyx Pharmaceutical Inc.	1	$20
Kyowa Kirin, Inc.	1	$20
Aytu Biopharma, Inc.	1	$20
Lifescan, Inc.	1	$19
Exact Sciences	1	$19
Recordati_rare_diseases_inc.	1	$18
Verity Pharmaceuticals Inc.	1	$17
Shire North American Group Inc	1	$15
Halozyme Inc	1	$13

How this compares

$997,685 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.

See all endocrinology, diabetes & metabolism providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$128,967

Medicare patients

486

Services billed

1,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Pittsburgh

Erin KershawPittsburgh$804K
Murray GordonPittsburgh$576K
Swarna VarmaPittsburgh$520K
Sachin BahlPittsburgh$162K
Peter GrondziowskiPittsburgh$143K
Patricia BononiPittsburgh$107K
Frederico ToledoPittsburgh$92K
Esra Karslioglu FrenchPittsburgh$73K
Mona Al MukaddamPhiladelphia$3.9M
Serge JabbourPhiladelphia$3.1M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →